ArticleScientific reports2017
Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Improving HER2 Diagnostics with Digital Real-Time PCR for Ultrafast, Precise Prediction of Anti-HER2 Therapy Response in Patients with Breast Cancer.Small methods · 2026Article
- Impact of Ethnic Differences and HER2 Protein Expression on the Age at Breast Cancer Diagnosis: A Mixed Methods Study.Cancer management and research · 2026Article
- Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.NPJ breast cancer · 2024Article
- In pursuit of sensitivity: Lessons learned from viral nucleic acid detection and quantification on the Raindance ddPCR platform.Methods (San Diego, Calif.) · 2022Review
- Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.BMC cancer · 2019Article
- Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer.NPJ breast cancer · 2019Article
- Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues.Medical oncology (Northwood, London, England) · 2018Article
- Digital PCR as a tool to measure HIV persistence.Retrovirology · 2018Review
- Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescentSouth Asian journal of cancerArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there are no recommended alternative assays for HER2 cases deemed equivocal by immunohistochemistry and fluorescent in situ hybridization. Digital PCR (ddPCR), a highly accurate method to determine DNA copy number, could be a robust alternative for clinical HER2 diagnostics. HER2 and CEP17 copy numbers were quantified using two ddPCR platforms (QX200 and RainDrop) in 102 samples of invasive breast cancers. Compared to routine assays, ddPCR gave a sensitivity and specificity of 82.8% and 97.3% respectively, with a kappa value of 0.833 (p < 0.001). Moreover, the method proved to be robust as the results from two platforms was highly correlated (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.